BAXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BAXTER INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$24.99−0.29 (-1.15%)
Close on Oct 19, 2026
- Market cap
- $12.94B
- P/E (TTM)
- –
- Dividend yield
- 2.08%
BAXTER INTERNATIONAL INC revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Products & Therapies | $2.08B | $1.29B | $1.39B | $1.33B | $1.95B | $1.26B | $1.31B | $1.34B | $1.32B | $1.23B | $1.32B | $1.26B | 70.1% | +6.7% |
| Healthcare Systems & Technologies | $801.00M | $705.00M | $827.00M | $773.00M | $767.00M | $704.00M | $784.00M | $752.00M | $748.00M | $667.00M | $795.00M | $744.00M | 27.1% | +4.4% |
| Pharmaceuticals | – | $621.00M | $668.00M | $632.00M | $612.00M | $581.00M | $643.00M | $588.00M | $602.00M | $578.00M | $597.00M | $580.00M | – | – |
| Kidney Care | – | – | – | – | – | – | – | – | $1.12B | $1.10B | $1.16B | $1.11B | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $563.00M | $298.00M | -$1.56B | $433.00M | $600.00M | $400.00M | -$1.25B | $462.00M | $433.00M | $372.00M | – | – | -6.2% |
| Medical Products & Therapies | $400.00M | $186.00M | $214.00M | $273.00M | $444.00M | $244.00M | $217.00M | $268.00M | $238.00M | $227.00M | $266.00M | $245.00M | -9.9% |
| Healthcare Systems & Technologies | $163.00M | $66.00M | $126.00M | $104.00M | $156.00M | $93.00M | $145.00M | $136.00M | $120.00M | $67.00M | $156.00M | $115.00M | +4.5% |
| Other | – | – | – | – | – | – | – | $2.00M | $9.00M | $4.00M | -$1.00M | $6.00M | – |
| Pharmaceuticals | – | $46.00M | $39.00M | $56.00M | $64.00M | $63.00M | $102.00M | $58.00M | $75.00M | $78.00M | $117.00M | $108.00M | – |
| Kidney Care | – | – | – | – | – | – | – | – | $83.00M | $159.00M | $92.00M | $96.00M | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.60B | $1.44B | $1.55B | $1.54B | $1.54B | $1.49B | $1.51B | $1.50B | $1.49B | $1.35B | $1.50B | $1.47B | 53.9% | +3.8% |
| International | $1.37B | $1.27B | $1.42B | $1.29B | $1.27B | $1.14B | $1.24B | $1.20B | $1.20B | $1.14B | $1.22B | $1.13B | 46.1% | +7.1% |
| Emerging markets | – | – | $398.00M | $355.00M | $344.00M | $297.00M | $349.00M | $347.00M | $347.00M | $307.00M | $358.00M | $353.00M | – | – |
| Rest of world | – | – | $1.02B | $936.00M | $930.00M | $838.00M | $894.00M | $852.00M | $855.00M | $835.00M | $866.00M | $779.00M | – | – |
From the segment and revenue-disaggregation notes of Baxter International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.